Monday, August 29, 2016
FDA has granted Orphan Drug Designation for Biotie's BTT1023 drug candidate for treatment of primary sclerosing cholangitis (PSC).
BTT1023 is currently being studied for PSC in Phase 2a study (BUTEO study). Says two-stage study design for BUTEO includes a pre-planned interim analysis expected in first half of 2017.
Source : reuters.com
